Tilray Brands, Inc. (TLRY.TO)
CAD 0.63
(-4.55%)
CAD 0.63
(-4.55%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -47.79 Million USD | 58.4% |
| 2022 | -1.27 Billion USD | -142.8% |
| 2021 | -246.4 Million USD | 786.85% |
| 2020 | 30.27 Million USD | -54.92% |
| 2019 | -47.87 Million USD | 367.85% |
| 2018 | -15.04 Million USD | 2062.99% |
| 2017 | -507.44 Thousand USD | -116.73% |
| 2016 | 4.37 Million USD | 4014.4% |
| 2015 | 115.11 Thousand USD | 97.8% |
| 2014 | -5.06 Million USD | -283.22% |
| 2013 | -1.32 Million USD | -2814.33% |
| 2012 | -604.14 Thousand USD | 53.98% |
| 2011 | -98.51 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 7.89 Million USD | 82.14% |
| 2023 FY | - USD | 58.4% |
| 2023 Q4 | -19.12 Million USD | -26.78% |
| 2023 Q3 | -15.08 Million USD | -267.39% |
| 2023 Q2 | -4.1 Million USD | 46.19% |
| 2023 Q1 | -7.63 Million USD | -9.91% |
| 2022 Q4 | -6.94 Million USD | 86.95% |
| 2022 Q2 | -38.36 Million USD | -5334.24% |
| 2022 Q3 | -53.21 Million USD | -38.69% |
| 2022 Q1 | 733 Thousand USD | -99.76% |
| 2022 FY | - USD | -142.8% |
| 2021 Q2 | -9.42 Million USD | 65.77% |
| 2021 Q1 | -27.54 Million USD | -408.64% |
| 2021 Q3 | 50.04 Million USD | 630.78% |
| 2021 FY | - USD | 786.85% |
| 2021 Q4 | 299.37 Million USD | 498.25% |
| 2020 Q2 | -69.23 Million USD | -318.6% |
| 2020 Q3 | -23.93 Million USD | 65.43% |
| 2020 FY | - USD | -54.92% |
| 2020 Q4 | 8.92 Million USD | 137.29% |
| 2020 Q1 | 31.67 Million USD | -35.35% |
| 2019 Q4 | 48.98 Million USD | 25.71% |
| 2019 Q1 | 23.97 Million USD | -42.83% |
| 2019 Q2 | 41.28 Million USD | 72.17% |
| 2019 Q3 | 38.96 Million USD | -5.61% |
| 2019 FY | - USD | 367.85% |
| 2018 Q1 | -2.72 Million USD | -186.01% |
| 2018 Q4 | 41.94 Million USD | 369.97% |
| 2018 FY | - USD | 2062.99% |
| 2018 Q3 | -15.53 Million USD | -157.12% |
| 2018 Q2 | 27.2 Million USD | 1099.34% |
| 2017 Q2 | 872.63 Thousand USD | 119.26% |
| 2017 FY | - USD | -116.73% |
| 2017 Q4 | 3.16 Million USD | 1161.9% |
| 2017 Q3 | -298.02 Thousand USD | -134.15% |
| 2017 Q1 | -4.53 Million USD | -296.77% |
| 2016 Q1 | 1.05 Million USD | 260.92% |
| 2016 FY | - USD | 4014.4% |
| 2016 Q3 | -4.6 Million USD | -597.14% |
| 2016 Q4 | 2.3 Million USD | 150.0% |
| 2016 Q2 | 926.49 Thousand USD | -12.58% |
| 2015 Q4 | 293.63 Thousand USD | 155.3% |
| 2015 Q3 | 115.01 Thousand USD | 147.38% |
| 2015 Q1 | -291.38 Thousand USD | 20.26% |
| 2015 FY | - USD | 97.8% |
| 2015 Q2 | -242.73 Thousand USD | 16.7% |
| 2014 Q1 | -8316.12 USD | 86.85% |
| 2014 Q4 | -365.43 Thousand USD | 84.96% |
| 2014 Q3 | -2.42 Million USD | -37386.56% |
| 2014 FY | - USD | -283.22% |
| 2014 Q2 | -6482.23 USD | 22.05% |
| 2013 Q1 | -7855.65 USD | -73.67% |
| 2013 Q4 | -63.26 Thousand USD | -33.93% |
| 2013 Q3 | -47.23 Thousand USD | -933.36% |
| 2013 Q2 | -4571.06 USD | 41.81% |
| 2013 FY | - USD | -2814.33% |
| 2012 Q2 | -20.45 Thousand USD | -49.81% |
| 2012 Q3 | -13.33 Thousand USD | 34.84% |
| 2012 Q4 | -4523.23 USD | 66.07% |
| 2012 Q1 | -13.65 Thousand USD | 24.11% |
| 2012 FY | - USD | 53.98% |
| 2011 Q2 | -3424.37 USD | 0.0% |
| 2011 Q4 | -17.99 Thousand USD | 72.63% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | -65.73 Thousand USD | -1819.75% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aurora Cannabis Inc. | 20.47 Million CAD | 333.457% |
| Avicanna Inc. | -7.35 Million CAD | -549.83% |
| Avant Brands Inc. | 4.83 Million CAD | 1088.379% |
| Cardiol Therapeutics Inc. | -27.87 Million CAD | -71.442% |
| Crescita Therapeutics Inc. | 45 Thousand CAD | 106317.778% |
| Knight Therapeutics Inc. | 40.89 Million CAD | 216.874% |
| MediPharm Labs Corp. | -10.47 Million CAD | -356.175% |
| OrganiGram Holdings Inc. | -207.61 Million CAD | 76.978% |
| Canopy Growth Corporation | -312.82 Million CAD | 84.721% |
| Willow Biosciences Inc. | -11.06 Million CAD | -332.131% |
| Auxly Cannabis Group Inc. | -10.82 Million CAD | -341.552% |